

PNAS

www.pnas.org

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21

Supporting Information for

Necroptosis-based CRISPR knockout screen reveals Neuropilin-1 as a critical host factor for early stages of murine cytomegalovirus infection

Rebecca K. Lane, Hongyan Guo, Amanda D. Fisher, Jonathan Diep, Zhao Lai, Yidong Chen, Jason W. Upton, Jan Carette, Edward S. Mocarski, and William J. Kaiser.

Corresponding authors: William J Kaiser, Hongyan Guo
Email: wkaiser@inzentx.com; hguo@gsu.edu

This PDF file includes:

- Supplementary materials and methods
- SI References
- Legends for Figures S1 to S5
- Figures S1 to S5

22 **SI Materials and Methods**

23

24 **Cell culture and preparation of virus stocks**

25 All cells were cultured in complete Dulbecco's Modified Eagle Medium (Sigma) supplemented
26 with 10% fetal bovine serum, 100 U/ml penicillin, and 100 U/ml streptomycin at 37°C with 5%
27 CO₂. The WT, M45mut, IE2-mCherry MCMV K181, and Mck-2mut viruses were propagated
28 and titered as previously described [1]. HSV-1 F ICP6mut virus was grown as previously
29 described [2].

30

31 **Construction of MCMV IE2-mCherry**

32 Recombineering for MCMV IE2-mCherry was generated using techniques previously described
33 [3]. The kanamycin resistance and leucine synthase (SacB) genes and associated regulatory
34 elements were PCR amplified from pTBE100 overhangs corresponding to MCMV genomic
35 sequence flanking HpaI sites surrounding IE2exon 1 (primers; JUp047, 5'-
36 TGCATTTGGCATTAAAACTATTGGTTCTAGTCATAAAACGGGCGGAGTTAATTCGA
37 GCTCGGTACCCGG -3' and JUp048, 5'-
38 AGCCCAATGCAACCTTACCCGGCCTGGGGGGCTCCGTTACCCGCTCGTTATCCCGG
39 GAAAAGTGCCACC -3'). Kanamycin-resistant, sucrose-sensitive
40 clones were selected and confirmed by RFLP analysis. IE2sB/K insertion deletes 76 nt of
41 MCMV sequence and introduces 2.9kb between the HpaI sites. The mCherry insertion mutation
42 was introduced by a second round of recombineering with a PCR amplicon amplified from
43 pmCherry-N1 (Clontech) (primers; U160, 5'-
44 GGCATTA AAAACTATTGGTTCTAGTCATAAAACGGGCGGAGTTGCTATTACCATGGT
45 GATGCGGTTTTG-3' and U161, 5'-

46 TGCAACCTTACCCGGCCTGGGGGGCTCCGTTACCCGCTCGTTGGACAAACCACAAC
47 TAGAATGCAGTG -3'). Colonies were screened for sucrose
48 resistance and kanamycin sensitivity, and positive clones were further confirmed by RFLP and
49 functional analyses. Genome integrity was confirmed by restriction digest and sequencing of the
50 target region of IE2. BAC-derived recombinant virus was generated and purified as previously
51 described [3].

52

53 **CRISPR screen**

54 The mouse GeCKOv2 pooled CRISPR gRNA library (Addgene pooled library #1000000052)
55 was packaged into lentivirus according to Sanjana *et al* [4]. The library was amplified and
56 packaged using a lentivirus expression system as previously described [5]. Briefly, 293FT cells
57 were transfected using lipofectamine 2000 (Invitrogen). 48 hours after transfection, supernatants
58 were collected, clarified by centrifugation (3,500 rpm for 10 min), filtered, and aliquoted for
59 storage at -80°C. Lentivirus containing the library was then used to transduce SVEC4-10
60 endothelial cells at MOI 0.3. Three transductions 24 hours apart were carried out and cells
61 selected with Puromycin for seven days. 2×10^8 library-containing cells were then infected with
62 the MCMV M45mut or HSV-1 ICP-6mut viruses (MOI 5) for one hour, then cultured in the
63 presence of 200 µg/mL phosphonoformic acid (PFA), an inhibitor of the herpes DNA
64 polymerase. Resistant cells were allowed to grow to 80% confluency before being subjected to
65 two additional rounds of infection and recovery. Genomic DNA was isolated from this
66 population and unselected library-containing cells, gRNA sequences were amplified, and
67 sequenced using an Illumina NextSeq 500 platform. The gRNA sequences against specific genes
68 were recovered after removal of the tag sequences using the FASTX-Toolkit

69 (http://hannonlab.cshl.edu/fastx_toolkit/) and cutadapt 1.8.1. The cut-off for candidate gene ‘hits’
70 was made using a published computational tool (MAGeCK version 0.5.4) which determines the
71 ranking of each hit by taking into account the number of sequencing reads for each unique guide,
72 the number of unique guides per gene, and the enrichment of a guide compared to the untreated
73 population [6].

74

75 **Plasmids and transgenic cell lines**

76 gRNA sequences against Nrp-1 were derived from the GeCKOv2 library, synthesized as
77 oligonucleotides, and cloned into lentiCRISPRv2 (Addgene #52961) according to published
78 protocol (<http://genome-engineering.org/gecko/>) [4]. Primers for cloning gRNA sequences were
79 as follows: Nrp-1 fw: CACCGCTCTTCAGGCGTTCTATCCA; Nrp-1 rev:
80 AAAGTGGATAGAACGCCTGAAGAGC. gRNAs were transfected into HEK-293T cells with
81 psPAX2 and VSV-G to generate lentivirus. Nrp-1 gRNA-containing lentivirus was then used to
82 transduce SVEC4-10 or 3T3-SA cells. Cells were then selected with Puromycin. Nrp-1 KO cells
83 were further sorted by flow cytometry to generate a clonal population. Murine Nrp-1 with N-
84 terminal 6X-His and HA tags was obtained from Addgene (Pinco-mNrp1, plasmid #21937) and
85 subcloned into pLV-EF1 α -IRES-Puro (Biosettia) using MluI and NheI. Primers were used to
86 recode the 20 bp stretch targeted by the Nrp-1 gRNA in order to make the transgene resistant to
87 the gRNA. All constructs were made by amplifying two fragments and joining the two by
88 assembly PCR. The Nrp-1 Δ C construct was cloned into pQCXIH (Takara) using AgeI and PacI.
89 Primers used for cloning are detailed in the below table. Plasmids were introduced into Nrp-1
90 KO cells by lentiviral transduction and reconstitution was verified by western blot and flow
91 cytometry for HA expression (Alexa Fluor 647-coupled anti-HA tag, R&D IC6875R).

Full-length Nrp-1	<p>Nrp-1 MluI fw: CTCACGCGTCCAGCGTCTGCAGCATGG</p> <p>Nrp-1 NheI rev: TCTGCTAGCGCCGCTCACGCCTCTG</p> <p>Nrp-1 recode fw: CAGCAGCGGTGTCCTTAGTATGGTCTTTTACACTGACAGCG</p> <p>Nrp-1 recode rev: ACTAAGGACACCGCTGCTGGAGCGGATCCGGCCAG</p>
Nrp-1 Δ a	<p>Nrp-1 Δa fw: GGAACCCTACCAGAGAATCATGGTGCTACAGAGCAGCATCTC</p> <p>Nrp-1 Δa rev: GAGATGCTGCTCTGTAGCACCATGATTCTCTGGTAGGGTTCC</p>
Nrp-1 Δ b	<p>Nrp-1 Δb fw: GCCAACTACAGTGTGCTACAGGAAGTGGAAGCACCTACAGC</p> <p>Nrp-1 Δb rev: GCTGTAGGTGCTTCCACTTCCCTGTAGCACACTGTAGTTGGC</p>
Nrp-1 Δ ab	<p>Nrp-1 Δab fw: GGAACCCTACCAGAGAATCATGGAAGTGGAAGCACCTACAGC</p> <p>Nrp-1 Δab rev: GCTGTAGGTGCTTCCACTTCCATGATTCTCTGGTAGGGTTCC</p>
Nrp-1 Δ C	<p>Nrp-1 AgeI fw: CTCACCGGTCCAGCGTCTGCAGCATGG</p> <p>Nrp-1 ΔC PacI rev: TCTTTAATTAAGGCACAGTACAGCACAAC</p>

95 5 x 10³ cells/well were seeded into 96-well plates in triplicate. After 18 hours, cells were infected
96 at MOI 10 with the lytic MCMV M45mut or HSV-1 ICP6mut viruses, or treated with 25 ng/mL
97 TNF α (PeproTech) + 5 μ M Emricasan (Aadooq biosciences). Cell viability was assessed by
98 adding the live cell-impermeable dye Sytox Green (Molecular probes, 50 nM) and labeling
99 nuclei with Hoechst 33342 (Molecular probes, 2 μ M). Cells were imaged hourly with four frames
100 per well with a Cytation 5 Imaging Reader (Biotek). Cell death was quantified as the percentage
101 of Sytox Green positive cells divided by Hoechst+ cells. Alternatively, cell survival was
102 determined indirectly by measuring intracellular ATP levels using the Cell Titer-Glo
103 Luminescent Cell Viability Assay kit (Promega) on a Synergy HT Multi-Detection microplate
104 reader (Bio-Tek).

105

106 **Western blotting**

107 The following antibodies were used for immunoblotting: rabbit anti-Nrp-1 (Cell Signaling
108 Technology #3725S), mouse anti-MCMV IE1/Croma101 (gift from Stipan Jonjic, University of
109 Rijeka), mouse anti- β -actin (Sigma #A5441), and rabbit anti-HA (Cell Signaling Technology
110 #3724).

111

112 **Immunofluorescence**

113 For immunofluorescence to quantify viral infection, adherent cells were fixed in 4%
114 paraformaldehyde and incubated in blocking buffer containing 10% goat serum, then incubated
115 with anti-IE1 (MCMV) or anti-ICP0 (HSV-1) antibody followed by Alexa Fluor 488-coupled
116 goat anti-mouse antibody (Invitrogen). The cells were counterstained with DAPI (Invitrogen) for

117 nuclei. Images were acquired on an LSM 510 Meta confocal fluorescence microscope (Carl
118 Zeiss).

119

120 **Viral growth assays**

121 WT MCMV viral yield in WT and Nrp-1 KO cells was determined by infecting cells at either a
122 low (0.1) or high (10) MOI. Cells and media were harvested after 8 and 48 (MOI 10) or 72 (MOI
123 0.1) hours and titered as before. Viral yield was calculated as the titer at 48 or 72 h.p.i. divided
124 by titer at 8 h.p.i. relative to the yield from WT cells.

125

126 **Infection with mCherry reporter virus**

127 Cells were infected in media containing Hoechst stain and either imaged at regular intervals with
128 a Cytation 5 Imaging Reader or collected and analyzed by flow cytometry. Infection rates were
129 quantified by counting mCherry+ cells as a percent of Hoechst+ cells using Image J. Rates of
130 infection in WT cells were set as the maximum rate of infection and infection rates in Nrp-1 KO
131 or soluble protein-treated cells are reported relative to the maximum rate. Quantification of
132 mCherry fluorescence intensity was performed 24 h.p.i. on an LSRII analyzer and data analyzed
133 by FlowJo software.

134

135 **Soluble Nrp-1 and anti-Nrp-1 antibody inhibition experiments**

136 Recombinant murine Nrp-1 (R&D Systems) and Nrp-2 (Sino Biological) were mixed with
137 MCMV IE2-mCherry at varying concentrations as indicated in the text and incubated at 37°C for
138 1 hour. The viral inoculum was then added to cells (MOI 1) and analyzed after 20-24 hours with
139 a Cytation 5 Imaging Reader or flow cytometry for mCherry+ cells.

140 For experiments using anti-Nrp-1 antibody to block infection, cells were cultured on coverslips
141 and pre-incubated with anti-Nrp-1 antibody (R&D AF566, 4 µg/ml) at 37°C for 30 minutes. In
142 some instances, 20 µg/ml of heparin sodium salt (Sigma) was incubated with the virus either
143 individually or in combination with anti-Nrp-1 antibody. Cells were then infected for six hours
144 with MCMV or HSV-1 at MOI 10. The percentage of infected cells was assessed by
145 immunofluorescence staining for IE1 or ICP0 in combination with DAPI.

146 To quantify differences in viral attachment to the cell surface, MCMV was pre-treated with
147 recombinant protein or blocking antibody as before and added to cells for 30 minutes at 4°C.
148 Cells were then harvested by scraping, and unbound virions washed away with PBS, followed by
149 three rounds of freezing at -80 °C and thawing. Virus titer was then quantified by plaque assay
150 on NIH3T3 cells.

151

152 **Mice and preparation of BMDMs**

153 *Nrp-1^{fl/fl}* C57BL/6 (JAX #005247) and *Cx3cr1-Cre^{ER}* C57BL/6 (JAX #020940) mice were
154 crossed to generate *Nrp-1^{fl/fl}; Cx3cr1-Cre^{ER+/-}* mice. Bone marrow from the femurs of two 8- to
155 10-week- old *Nrp-1^{fl/fl}; Cx3cr1-Cre^{ER+/-}* mice and *Nrp-1^{fl/fl}* littermate controls was flushed with
156 PBS. Harvested cells were then plated in complete DMEM supplemented with 20% L929-
157 conditioned media and 2 µM 4-hydroxy-tamoxifen (Sigma). After seven days, 1 x 10⁶ cells were
158 collected for Western blot of Nrp-1 expression and 1.5 x 10⁴ cells were seeded in a 96-well plate.
159 Infection with MCMV M45mut was done as described above and survival quantified by Cell
160 Titer-Glo Luminescent Cell Viability Assay. Alternatively, cells were seeded in 6-well plates and
161 infected with WT MCMV. Six hours post infection, cells were collected, lysed, and whole-cell
162 lysates analyzed by Western blot for IE1 expression.


163 **SI References**

164

- 165 1. Upton, J.W., W.J. Kaiser, and E.S. Mocarski, *Virus inhibition of RIP3-dependent*
166 *necrosis*. Cell Host Microbe, 2010. **7**(4): p. 302-13.
- 167 2. Guo, H., et al., *Herpes simplex virus suppresses necroptosis in human cells*. Cell Host
168 Microbe, 2015. **17**(2): p. 243-51.
- 169 3. Hilterbrand, A.T., et al., *Murine Cytomegalovirus Deubiquitinase Regulates Viral*
170 *Chemokine Levels To Control Inflammation and Pathogenesis*. MBio, 2017. **8**(1).
- 171 4. Sanjana, N.E., O. Shalem, and F. Zhang, *Improved vectors and genome-wide libraries for*
172 *CRISPR screening*. Nat Methods, 2014. **11**(8): p. 783-784.
- 173 5. Joung, J., et al., *Genome-scale CRISPR-Cas9 knockout and transcriptional activation*
174 *screening*. Nat Protoc, 2017. **12**(4): p. 828-863.
- 175 6. Li, W., et al., *MAGeCK enables robust identification of essential genes from genome-*
176 *scale CRISPR/Cas9 knockout screens*. Genome Biol, 2014. **15**(12): p. 554.


177 SI Figures and Legends

178



179


180 **Fig S1. Nrp-1 is uniquely utilized for MCMV, not HSV-1 infection.** (A) Screen results for
181 HSV-1. Hits are stratified along a vertical axis according to significance and arbitrarily spread
182 along the horizontal axis. The size of the circle and the number next to the gene name both
183 indicate the number of gRNAs for that gene that were found in the resistant population. Colors
184 indicate gene ontology. (B) Cell viability in WT and Nrp-1 KO SVEC4-10 cells infected with
185 HSV-1 ICP6mut (MOI 10). After 24 hours, survival was measured by Cell Titer Glo
186 Luminescent Cell Viability Assay. Infections were performed in triplicate with two independent
187 experiments.



188

189 **Fig S2. Soluble Nrp-1 reduces infection rates in SVEC4-10 cells.** (A) Coomassie blue stain of
 190 recombinant Nrp-1 and Nrp-2. Proteins were run on an SDS-PAGE gel under reducing
 191 conditions. (B) MCMV IE2-mCherry was incubated with soluble recombinant Nrp-1, Nrp-2, or
 192 media alone for one hour at 37°C before being added to WT SVEC4-10 cells at MOI 1. Cells
 193 were analyzed by flow cytometry 20 h.p.i. (C) Cell death in cells infected in triplicate with
 194 MCMV M45mut virus pre-treated with soluble Nrp-1 as in (B). Cell death was determined by
 195 staining cells with Sytox and Hoechst and imaging every hour. At least two replicates were
 196 performed per experiment.

197



198

199 **Fig S3. The extracellular domains of Nrp-1 facilitate MCMV infection.** Immunoblot (A) and

200 flow cytometry (B) detecting expression of HA-tagged Nrp-1 mutants in SVEC4-10 Nrp-1 KO cells.

201 (C) Fluorescence microscopy for IE2-mCherry expression in SVEC4-10 WT or Nrp-1 KO cells


202 reconstituted with full-length and deletion Nrp-1 mutants. Cells were infected with MCMV IE2-

203 mCherry (MOI 1) in triplicate and imaged after 20 h.p.i. (D) Quantification of survival of Nrp-1

204 mutant-expressing cells following MCMV M45mut infection (MOI 10). Infection was performed


205 in triplicate. After 24 hours, survival was measured by Cell Titer Glo Luminescent Cell Viability

206 Assay. At least two replicates were performed per experiment. Error bars indicate SEM.
207 Significance was determined using a one-way ANOVA with Bonferroni's multiple comparisons
208 test (** $p < 0.0001$ ** $p < 0.001$ * $p < 0.01$).



209

210 **Fig S4. Cell death and viral titers are reduced in Nrp-1 KO 3T3-SA cells.** (A) Cell death in
 211 3T3-SA Nrp-1 KO cells was determined by Sytox uptake as described in Fig. 1F. (B) Cell
 212 survival in WT and Nrp-1 KO 3T3-SA cells infected with MCMV M45mut (MOI 10), or treated
 213 with 25 ng/mL TNF α + 5 μ M Emricasan or media alone. After 24 hours, survival was
 214 determined by Cell Titer Glo Luminescent Cell Viability Assay. (C) WT or Nrp-1 KO SVEC4-
 215 10 cells were infected at the indicated MOI with WT MCMV for one hour and harvested after 48
 216 (MOI 10) or 72 (MOI 0.1) h.p.i. and viral titer determined by plaque assay. Values shown are
 217 relative to WT counterparts. All infections were performed in triplicate and at least two
 218 replicates were performed per experiment. Error bars indicate SEM. Significance was
 219 determined using a student's t-test (***) p<0.0001).



221 **Fig S5. Soluble Nrp-1 inhibits MCMV infection in fibroblasts and macrophages.** (A)
222 MCMV M45mut virus was pretreated with soluble Nrp-1 for one hour before infecting 3T3-SA
223 cells. Cell death was determined by staining cells with Sytox and Hoechst and imaging every
224 hour. (B) Cells were infected with MCMV IE2-mCherry that had been pretreated for one hour
225 with Nrp-1. Red fluorescence was quantified at 20 h.p.i. by flow cytometry. (C) 3T3-SA cells
226 were infected with MCMV IE2-mCherry pre-treated with varying concentrations of soluble Nrp-
227 1 and imaged 20 h.p.i. (D) Quantification of mCherry + cells from (C). Significance was
228 determined by using a one-way ANOVA with Dunnett's multiple comparisons test. (E) Percent
229 infection in IC-21 cells in the presence of soluble neuropilins. MCMV was pretreated with 10
230 $\mu\text{g}/\text{mL}$ soluble Nrp-1 or 15 $\mu\text{g}/\text{mL}$ Nrp-2 for one hour prior to infecting IC-21 cells. Cells were
231 fixed six h.p.i. and percent infection quantified by staining for IE1 and DAPI. Significance was
232 determined by using a one-way ANOVA with Dunnett's multiple comparisons test. (F) Viral
233 yield in IC-21 cells infected with MCMV (MOI 1) in the presence or absence of 10 $\mu\text{g}/\text{mL}$ Nrp-1
234 for 48 hours. Cell lysates were titered by plaque assay. (G) Percent infection in the presence of
235 Nrp-1 blocking antibody. IC-21 cells were pre-incubated with anti-Nrp1 antibody (4 $\mu\text{g}/\text{ml}$),
236 heparin (20 $\mu\text{g}/\text{ml}$), or both for 30 minutes and then infected for six hours with MCMV. The
237 percentage of infected cells was assessed by staining for IE1 and DAPI. Significance was
238 determined by using a one-way ANOVA with Bonferroni's multiple comparisons test. (H)
239 Quantification of viral attachment at the cell surface in the presence of Nrp-1 blocking antibody.
240 IC-21 cells were pre-incubated with anti-Nrp1 antibody (4 $\mu\text{g}/\text{ml}$) or media alone for one hour
241 before being added to IC-21 cells in triplicate at MOI 1 and incubated for 30 minutes at 4°C.
242 Cells were harvested by scraping and unbound virions washed away. The amount of adhered
243 virus was then quantified by plaque assay. (I) Western blot for level of Nrp-1 knockout in

244 BMDMs collected from mice of the indicated genotypes and treated with 2 μ M 4-hydroxy-
245 tamoxifen for seven days to induce Cre activity. (J) Cell survival in BMDMs treated as in (I) and
246 infected in triplicate with MCMV M45mut (MOI 10). 24 h.p.i., cell survival was quantified by
247 Cell Titer Glo Luminescent Cell Viability Assay. (K) SVEC4-10, 3T3-SA, and IC-21 cells were
248 infected with WT or MCK2-deficient virus (Mck2mut) at MOI 10 and 6 h.p.i. stained for IE1
249 expression by immunofluorescence. All infections were performed in triplicate and at least two
250 replicates were performed per experiment. All microscopy data was quantified by taking the
251 average from four images. Significance was determined using a student's t-test unless otherwise
252 stated (** $p < 0.0001$, ** $p < 0.001$).